APA (7th ed.) Citation

Li, J., Liao, C., Liu, Z., Xiong, H., Cai, J., & Liu, T. (2024). PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis. Technology in cancer research & treatment, 23, 15330338241305700. https://doi.org/10.1177/15330338241305700

Chicago Style (17th ed.) Citation

Li, Jun, Chun Liao, Zhaohui Liu, Hu Xiong, Jing Cai, and Tiande Liu. "PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis." Technology in Cancer Research & Treatment 23 (2024): 15330338241305700. https://doi.org/10.1177/15330338241305700.

MLA (9th ed.) Citation

Li, Jun, et al. "PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis." Technology in Cancer Research & Treatment, vol. 23, 2024, p. 15330338241305700, https://doi.org/10.1177/15330338241305700.